CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×HMG-CoA reductase inhibitor (statin)
Updated · Methodology
Mechanism
The liver clears lovastatin through the enzyme CYP3A4. Strong inhibitors of this enzyme raise lovastatin blood levels and with them the risk of muscle damage (myopathy) and muscle breakdown (rhabdomyolysis) (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir is taken only with a booster, ritonavir or cobicistat, and in this regimen it inhibits CYP3A (darunavir SmPC, European Medicines Agency, EMA; darunavir label, US Food and Drug Administration, FDA). The pair has not been studied, but lovastatin levels are expected to rise markedly (darunavir SmPCs, AEMPS and EMA). Human immunodeficiency virus (HIV) protease inhibitors, the class darunavir belongs to, appear by name among the strong CYP3A4 inhibitors in the lovastatin SmPC (lovastatin SmPC, AEMPS).
Symptoms
Myopathy shows as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It sometimes progresses to rhabdomyolysis with acute kidney failure caused by myoglobin in the urine, in rare cases fatal (lovastatin SmPC, AEMPS). Muscle pain, tenderness or weakness is of particular concern when it comes with malaise or fever (lovastatin label, US Food and Drug Administration, FDA). Since darunavir came to market, rhabdomyolysis linked to co-administration with statins has been reported (darunavir/cobicistat FDA label).
Management
The combination is contraindicated. Lovastatin is on the darunavir list of contraindicated drugs (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA; darunavir label, US Food and Drug Administration, FDA). Under the lovastatin documents, lovastatin must not be used with any human immunodeficiency virus (HIV) protease inhibitor (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; lovastatin FDA label). The contraindication applies with either booster, ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat SmPCs, EMA; darunavir and darunavir/cobicistat FDA labels). If the patient needs a statin during darunavir treatment, start atorvastatin at 10 mg once daily and increase the dose gradually according to clinical response (darunavir SmPC, AEMPS). With darunavir/cobicistat, start any statin other than lovastatin and simvastatin at the lowest dose and titrate it while monitoring safety (darunavir/cobicistat SmPC, EMA). Keep atorvastatin and rosuvastatin at no more than 20 mg a day (darunavir/cobicistat FDA label). Tell the patient to report unexplained muscle pain, tenderness or weakness at once (lovastatin SmPC, AEMPS). If the patient has nevertheless taken lovastatin with darunavir and muscle symptoms appear, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal in the absence of strenuous exercise (lovastatin SmPC, AEMPS). If myopathy is suspected, stop lovastatin at once. In most cases, muscle symptoms and CK rises resolved after prompt withdrawal (lovastatin FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: Lovastatin Tablets USP (lovastatin) prescribing information (2026)– FDA, DailyMed setid df7ddf4f-d569-431e-81f1-9129d7043150 (Lupin Pharmaceuticals), revisión 05/2026 (versión 17), Clinical Pharmacology (tabla I), Contraindications, Warnings (Myopathy/Rhabdomyolysis) y Precautions
- AEMPS: Ficha técnica: Lovastatina (Taucor 20 mg, nº registro 58757), sección 4.3 (2025)– AEMPS, CIMA, nº registro 58757 (Taucor 20 mg, Alfasigma España), revisión 09/2025 (texto revisado 04/2023), secciones 4.3, 4.4 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3